SAN DIEGO, CA – Shareholders of Bionano Genomics, Inc., a company specializing in laboratory analytical instruments, participated in the 2024 Annual Meeting of Stockholders on Monday, where they voted on several key proposals, according to a recent SEC filing.
During the meeting, a total of 30,047,684 shares were represented in person, virtually, or by proxy, which accounts for approximately 44.94% of the shares outstanding as of the April 22, 2024, record date. The shareholders elected three Class III Directors to serve until the 2027 Annual Meeting or until their successors are appointed. Christopher Twomey, Yvonne Linney, Ph.D., and Aleksander Rajkovic, M.D., Ph.D., were elected with votes of 10,442,715, 10,682,829, and 10,810,303 respectively. Votes withheld and broker non-votes were also reported for each candidate.
In addition to the election of directors, the compensation of the company's named executive officers was approved on an advisory basis. The proposal received 9,508,999 votes for, 1,771,611 against, and 642,388 abstentions, with 18,124,686 broker non-votes.
The third proposal put forth was the ratification of BDO USA, P.C. as the independent registered public accounting firm for Bionano Genomics for the fiscal year ending December 31, 2024. This proposal was passed with 26,950,772 votes for, 2,788,563 against, and 308,349 abstentions.
Bionano Genomics, Inc., headquartered at 9540 Towne Centre Drive, Suite 100, San Diego, California, is incorporated in Delaware and operates under the trading symbol NASDAQ:BNGO. The company's President and Chief Executive Officer, R. Erik Holmlin, Ph.D., confirmed the accuracy of the report filed with the SEC on June 21, 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.